
OmniAb Inc (OABI) Stock Forecast & Price Target
OmniAb Inc (OABI) Analyst Ratings
Bulls say
OmniAb is well positioned because its Biological Intelligence platform, proprietary transgenic animal models, and deep immune-repertoire datasets create a differentiated discovery engine that helps partners identify optimized antibodies and other binders faster than conventional approaches. Its outlook is further supported by a growing royalty aggregation model with a steady cadence of milestone revenue, potential milestones of more than $3B, a 425-program portfolio with 98% downstream economics, and a newly disclosed $370M Lilly collaboration that validates the platform. Management also expects xPloration revenue of $2M–$3M in 2026, with doubling in 2027 and again in 2028, while raised 2026 year-end cash guidance of $49M–$53M reinforces financial flexibility to fund expansion.
Bears say
OmniAb is exposed to a business model where most value depends on downstream milestones and royalties, so any delay or failure in partner asset approvals would directly weaken valuation and cash flow visibility. Near-term caution in biopharma capital spending could slow program adds, while a surge in AI-driven sequence design may reduce demand for animal-based discovery methods and leave its platform vulnerable to commoditization or patent pressure. With revenue tied to partner growth and deal terms, even modest setbacks in adoption or competitive differentiation could materially impair future royalties and long-term attractiveness.
This aggregate rating is based on analysts' research of OmniAb Inc and is not a guaranteed prediction by Public.com or investment advice.
OmniAb Inc (OABI) Analyst Forecast & Price Prediction
Start investing in OmniAb Inc (OABI)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About OmniAb Inc (OABI) Forecast
OmniAb Inc (OABI) Analyst Forecast & Price Prediction
Start investing in OmniAb Inc (OABI)
Order type
Buy in
Order amount
Est. shares
0 shares